NCT05487560View on ClinicalTrials.gov

An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding

CompletedOBSERVATIONAL
Enrollment

4,133

Participants

Timeline

Start Date

April 18, 2019

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months
Interventions
DRUG

Esomezol Cap

Esomezol Cap, Once daily administered per the locally approved product information

Trial Locations (1)

05545

Hanmi Pharmaceutical Company Limited, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05487560 - An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding | Biotech Hunter | Biotech Hunter